{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 49,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "other",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline-like arrow to represent innovation and expansion into new indications.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/13",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.58
      },
      "kind": "diagram",
      "text": "Continued innovation, expanding into broader patient populations",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fe0fe79-9530-407e-8ded-a11076a3c59d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.43,
        "y": 0.28
      },
      "kind": "image",
      "text": "ULTOMIRIS (ravulizumab-cwvz)",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19eddc30-b918-4794-b9a6-9da02425ee60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.12,
        "y": 0.28
      },
      "kind": "image",
      "text": "SOLIRIS (eculizumab)",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37b8eea4-404a-4f3d-832c-78aa2fc13886",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.67,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "ALXN1720 C5 bi-specific mini-body (VHH Ab)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cda3741a-d7ec-4afa-bb0b-24e0ef5d2eff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Q2W = every 2 weeks; IV = intravenous; Q8W = every 8 weeks; QW = once-weekly; SC = subcutaneous; VHH Ab = single domain antibody; PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome; gMG = generalised myasthenia gravis; NMOSD = neuromyelitis optica spectrum disorder; HSCT-TMA = haematopoietic stem cell transplant-associated thrombotic microangiopathy; CSA-AKI = cardiac surgery-associated acute kidney injury; DM = dermatomyositis.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee9e741b-a9a5-4ec4-b04f-d4b7020080c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Diverse C5 inhibitor portfolio, optimised for differentiated indication selection",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43ca24db-1283-4579-845d-70526f13c692",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Foundation in terminal complement (C5) inhibition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3356456b-a894-46b5-9cd9-ee728b682b5f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "41f21960-a52a-4688-be55-5a3ddb113131",
      "evidence": "The arrow at the bottom indicates a progression of innovation over time.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 19,
      "from": 10,
      "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 10,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b",
      "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs",
      "position": 1,
      "objective": "How AstraZeneca's pipeline addresses high unmet medical needs",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.6,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}